Memphasys

Memphasys CROIC

The Cash Return on Invested Capital (CROIC) of Memphasys (MEM.AX) as of Oct 19, 2026 is -29.49 %. In the previous year, Cash Return on Invested Capital (CROIC) was -23.01 % — a change of 28.16% (lower).

CROIC

-29.49 %

YoY

28.16%

Last updated:

Cash Return on Invested Capital (CROIC) of Memphasys is 2026 -29.49 % . Cash Return on Invested Capital (CROIC) of Memphasys was 2025 -23.01 % . It decreases by 28.16% lower compared to the previous year.

The Memphasys CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2019
-11.86 AUD
Jan 1, 2020
-27.88 AUD
Jan 1, 2021
-21.19 AUD
Jan 1, 2022
-19.77 AUD
Jan 1, 2023
-23.47 AUD
Jan 1, 2024
-33.22 AUD
Jan 1, 2025
-23.01 AUD
Jan 1, 2026
-29.49 AUD
The Memphasys CROIC history
YEARCROICYoY
-29.49 %+28.16%
-23.01 %-30.75%
-33.22 %+41.56%
-23.47 %+18.72%
-19.77 %-6.71%
-21.19 %-23.99%
-27.88 %+134.98%
-11.86 %-38.60%
-19.32 %-35.32%
-29.88 %+49.05%
-20.04 %-49.75%
-39.89 %+106.08%
-19.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Cash Return on Invested Capital (CROIC) of Memphasys is -29.49 % in 2026.

Cash Return on Invested Capital (CROIC) of Memphasys changed from -23.01 % to -29.49 %, representing a 28.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Memphasys since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Memphasys with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Memphasys

All Key Metrics — Memphasys